These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6304790)

  • 1. Bordetella pertussis toxins.
    Wardlaw AC; Parton R
    Pharmacol Ther; 1982; 19(1):1-53. PubMed ID: 6304790
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologically active components and properties of Bordetella pertussis.
    Morse SI
    Adv Appl Microbiol; 1976; 20():9-26. PubMed ID: 11644
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular aspects of Bordetella pertussis pathogenesis.
    Locht C
    Int Microbiol; 1999 Sep; 2(3):137-44. PubMed ID: 10943406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogenetic significance of Bordetella pertussis toxin].
    Finger H
    Immun Infekt; 1985 Apr; 13(2):47-9. PubMed ID: 2860059
    [No Abstract]   [Full Text] [Related]  

  • 5. Further contributions to an improved pertussis vaccine: II. New findings in the development of a pertussis vaccine.
    Robbel L; Hungerer KD; Aktories K
    Behring Inst Mitt; 1984 Nov; (76):110-2. PubMed ID: 6098261
    [No Abstract]   [Full Text] [Related]  

  • 6. [Whooping cough--a toxicosis?].
    Finger H; Wirsing von König CH
    Dtsch Med Wochenschr; 1986 Jun; 111(24):950-4. PubMed ID: 2872045
    [No Abstract]   [Full Text] [Related]  

  • 7. Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013.
    Quinlan T; Musser KA; Currenti SA; Zansky SM; Halse TA
    Mol Cell Probes; 2014 Aug; 28(4):138-40. PubMed ID: 24365130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bordetella type III secretion system: its application to vaccine development.
    Abe A; Nagamatsu K; Watanabe M
    Microbiol Immunol; 2008 Feb; 52(2):128-33. PubMed ID: 18380810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biological activities of Bordetella pertussis mutants lacking the ability to produce filamentous hemagglutinin with similar activities of other smooth strains.
    Watanabe M; Munoz JJ
    Microbiol Immunol; 1982; 26(10):965-9. PubMed ID: 6298581
    [No Abstract]   [Full Text] [Related]  

  • 10. Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development.
    Carbonetti NH; Wirsing von König CH; Lan R; Jacob-Dubuisson F; Cotter PA; Deora R; Merkel TJ; van Els CA; Locht C; Hozbor D; Rodriguez ME
    Clin Vaccine Immunol; 2016 Nov; 23(11):842-850. PubMed ID: 27655886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Toxic factors of Bordetella pertussis, with special reference to leukocytosis-promoting factor, histamine-sensitizing factor and hemagglutinins (author's transl)].
    Sato Y
    Tanpakushitsu Kakusan Koso; 1976 Nov; Suppl():164-83. PubMed ID: 194282
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis vaccine.
    Robinson A; Ashworth LA; Irons L
    Lancet; 1982 Jul; 2(8289):108. PubMed ID: 6123801
    [No Abstract]   [Full Text] [Related]  

  • 14. High prevalence of currently circulating Bordetella pertussis isolates not producing vaccine antigen pertactin in Slovenia.
    Kastrin T; Barkoff AM; Paragi M; Vitek MG; Mertsola J; He Q
    Clin Microbiol Infect; 2019 Feb; 25(2):258-260. PubMed ID: 30691616
    [No Abstract]   [Full Text] [Related]  

  • 15. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells.
    Tuomanen E; Weiss A
    J Infect Dis; 1985 Jul; 152(1):118-25. PubMed ID: 2861240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bordetella pertussis: multiple attacks on host cell cyclic AMP regulation.
    Wolff J; Cook GH; Goldhammer AR; Londos C; Hewlett EL
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 17():161-72. PubMed ID: 6328913
    [No Abstract]   [Full Text] [Related]  

  • 18. Further contributions to an improved pertussis vaccine: I. Molecular mechanisms of pertussis toxin.
    Aktories K; Jakobs KH; Robbel L
    Behring Inst Mitt; 1984 Nov; (76):106-9. PubMed ID: 6098260
    [No Abstract]   [Full Text] [Related]  

  • 19. Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia.
    Tuomanen E; Weiss A; Rich R; Zak F; Zak O
    Dev Biol Stand; 1985; 61():197-204. PubMed ID: 2872105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis and pertussis vaccine: 1990.
    Mortimer EA
    Adv Pediatr Infect Dis; 1990; 5():1-33. PubMed ID: 2183817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.